Novel Antimicrobial peptides effective against avian pathogenic Escherichia coli (APEC) and SalmonellaThe Need: Microbial infections, particularly those caused by antibiotic-resistant pathogens like APEC and Salmonella, pose a significant commercial and health challenge. The demand for effective and innovative bioactive peptides capable of inhibiting these pathogens is escalating. Biotechnology companies and researchers are seeking novel approaches to combat infections and improve microbial therapeutics. To meet this need, we present a cutting-edge technology capable of identifying bioactive peptides in cell-free supernatants of probiotic strains, Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis Bb12. The Technology: Our proprietary technology employs state-of-the-art LC-MS/MS analysis, utilizing HyperSepTM HypercarbTM SPE cartridge, to identify bioactive peptides secreted by LGG and Bb12. These peptides demonstrate inhibitory potential against antibiotic-resistant pathogens, making them promising candidates for therapeutic development. Commercial Applications:
Benefits/Advantages:
Patents
|
Tech IDT2022-002 CollegeCollege of Food, Agricultural, and Environmental Sciences (CFAES) Licensing ManagerDahlman, Jason "Jay" InventorsCategories |